An investigator-initiated clinical study of Telomelysin-radiation combination therapy for esophageal cancer
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Telomelysin (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- 16 Oct 2019 According to a Chugai Pharmaceutical media release, Oncolys initiated dosing of this trial in July 2017.
- 24 Jul 2017 According to an Oncolys Biopharma media release, interim results from this trial will be presented at the 15th Annual Meeting of the Japanese Society of Medical Oncology (JSMO2017).
- 17 Mar 2017 New trial record